Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study of Sacituzumab Govitecan as a single agent in patients with persistent or recurrent endometrial cancers

Trial Profile

A phase 2 study of Sacituzumab Govitecan as a single agent in patients with persistent or recurrent endometrial cancers

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacituzumab govitecan (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Aug 2018 New trial record
    • 30 Jul 2018 According to an Immunomedics media release, the company collaborated with Yale University to evaluate Sacituzumab Govitecan in Endometrial and Cervical Cancers (298367). Alessandro D. Santin, MD, Professor of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, is a principle investigator of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top